ReviewDrug design, development and therapy2025
An Updated Review of Molecular Mechanisms Implicated with the Anticancer Potential of Diosgenin and Its Nanoformulations.
Review in Drug design, development and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Green Synthesis of Silver Nanoparticles from Cotoneaster lacteus: Experimental Characterization and Mechanistic Insights from Biological Assays, DFT and Molecular Docking Studies.Applied biochemistry and biotechnology · 2026Article
- Plant-Derived Bioactive Compounds and Their Therapeutic Potential in Cancer.International journal of molecular sciences · 2026Review
- DcMYB5 transcription factor regulates the biosynthesis of diosgenin by directly repressing CYP90B gene expression in Dioscorea composita.Plant cell reports · 2026Article
- Harnessing Endophytic Fungi as a Sustainable Source of Novel Anticancer Agents: Opportunities, Challenges, and Future Directions.Molecules (Basel, Switzerland) · 2026Review
- Therapeutic potential of diosgenin in hepatocellular carcinoma through molecular mechanisms and nanodelivery strategies.Discover oncology · 2026Review
- Phytochemical evaluation, nutritional and pharmacological values ofFrontiers in chemistry · 2026Review
- The role of hypoxia-inducible factor-1α on colon cancer progression and metastasis.International journal of clinical oncology · 2025Review
- Inhibition of (p)ppGpp Synthesis and Membrane Fluidity Modulation by Diosgenin: A Strategy to SuppressInternational journal of molecular sciences · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Dietary components have gained broader recognition in preventing and managing numerous human carcinomas. Plant-derived natural compounds offer several benefits, including their limited toxicity and multi-targeted agents in modulating deregulated oncogenic pathways, including PI3K/AKT, NF-κB/STAT3, and HIF-1α, and hence, they emerged as better chemotherapeutic alternatives. Diosgenin (phytosteroidal saponin) and its nanoformulations have been extensively reported to impact cancer progression and metastasis. Research has indicated that diosgenin and its nanoformulations possess significant anticancer potential with improved bioavailability. However, novelty of this review relies on compiling the updated anticancer role of diosgenin and its nanoformulations in modulating numerous oncogenic targets associated with carcinogenesis and metastasis. Diosgenin has also been utilized with traditional therapies to enhance the sensitivity of cancerous cells towards normal chemotherapeutic processes. More focus should be given to gain detailed insights about the mechanisms associated with the anticancer potential of diosgenin and its nanoformulations, which can further potentiate its candidature in developing efficient cancer therapies. However, more preclinical studies are warranted to exploit the anticancer efficacy of this plant-based compound in an efficient manner.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.